Join the On-Demand Highlights Meeting at soho.click/highlightsVE.
To enter, just type in your email address.
Digital Agenda
The SOHO Highlights: State of the Art & Next Questions meeting will be held on October 27, 2021 as a virtual event. The “SOHO Highlights” meeting is designed to provide participants with an overview of the latest advances in hematologic malignancies and a preview of where the field is going next. Investigators from around the world will join the meeting for a day of learning and interactive, virtual discussion with the speakers. Each presentation is 25 minutes followed by a 10-minute, live Questions & Answer session with the audience. Note that the Zoom webinar platform will be utilized to facilitate interaction with attendees.
You may view the SOHO Highlights session line-up in the following Digital Agenda. Those that have registered may select the link to join the session directly. Note that all times in the program are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC -5).
Wednesday, October 27, 2021 | |||||
---|---|---|---|---|---|
Part I | Introduction | Hagop Kantarjian - MD Anderson Cancer Center | View Presentation | ||
Part I | State of the Art & Next Questions: Acute Lymphoblastic Leukemia | Elias Jabbour - MD Anderson Cancer Center | View Presentation | ||
Part I | State of the Art & Next Questions: Acute Myeloid Leukemia | Hagop Kantarjian - MD Anderson Cancer Center | View Presentation | ||
Part I | State of the Art & Next Questions: Cellular Therapy | Sergio Giralt - Memorial Sloan Kettering Cancer Center | View Presentation | ||
Part I | State of the Art & Next Questions: Chronic Lymphocytic Leukemia | Jennifer Brown - Dana-Farber Cancer Institute | View Presentation | ||
Part I | State of the Art & Next Questions: Chronic Myeloid Leukemia | Jorge Cortes - Georgia Cancer Center | View Presentation | ||
Part II | State of the Art & Next Questions: Multiple Myeloma | Sagar Lonial - Emory University Winship Cancer Institute | View Presentation | ||
Part II | State of the Art & Next Questions: Indolent B-Cell Lymphoma | Laurie Sehn - BC Cancer Agency | View Presentation | ||
Part II | State of the Art & Next Questions: T-Cell Lymphoma | Barbara Pro - Robert H Lurie Cancer Center, Northwestern University | View Presentation | ||
Part II | State of the Art & Next Questions: Mantle Cell Lymphoma | Brad Kahl - Washington University School of Medicine in St Louis | View Presentation | ||
Part II | State of the Art & Next Questions: Hodgkin Lymphoma | Craig Moskowitz - University of Miami Health System | View Presentation | ||
Part II | State of the Art & Next Questions: Aggressive B-Cell Lymphoma | Grzegorz Nowakowski - Mayo Clinic Rochester | View Presentation | ||
Part II | State of the Art & Next Questions: Myelodysplastic Syndromes | Guillermo Garcia-Manero - MD Anderson Cancer Center | View Presentation | ||
Part II | State of the Art & Next Questions: Myeloproliferative Neoplasms | Srdan Verstovsek - The University of Texas MD Anderson Cancer Center | View Presentation | ||
Part II | Closing Remarks | Jennifer Brown - Dana-Farber Cancer Institute | View Presentation |